Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03519113
Other study ID # GC1102_P2b/3
Secondary ID
Status Active, not recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date March 29, 2018
Est. completion date September 30, 2022

Study information

Verified date October 2019
Source Green Cross Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a clinical study for GC1102 to demonstrate preventing the recurrence of hepatitis B virus (HBV) infection following liver transplantation and a dose-finding study to determine its optional dose.


Description:

GC1102 is a new recombinant hepatitis B immunoglobulin (HBIG) from Chinese Hamster Ovary (CHO) cells. It is a monoclonal antibody and has high affinity and avidity to hepatitis B surface antigen and several advantages compared to HBIG derived from blood plasma of human donors. Volunteers will participate in the study, receive 24-week treatment with 80,000/100,000 IU of GC1102 or I.V HBIG and be followed up till 28 weeks.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 186
Est. completion date September 30, 2022
Est. primary completion date March 31, 2022
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria:

1. Subject who was informed of, and fully understood, all aspects of the study and has provided voluntary written consent for participation in the study

2. Subject aged over 19 years at the time of consent provided

3. Subject with planned liver transplantation due to HBV-related end-stage liver disease such as cirrhosis, liver cancer and fulminant hepatic failure

4. Subject with HBsAg(+)

Exclusion Criteria:

1. Subject with planned reoperation following liver transplantation

2. Subject with hemophilia

3. Subject with a history of venous or arterial thrombosis

4. Subject with HAV, HCV or HIV infection

5. Subject with immunodeficiency or immunosuppression due to whole body steroids before liver transplantation

6. Subject with hemolytic or blood loss anemia

7. Subject with IgA deficiency

8. Subject with a history of malignant tumor within the last 5 years, excluding primary liver cancer

9. Subject with moderate to severe kidney disease (serum creatinine > 20mg/dL or anuria, kidney failure or dialysis)

10. Subject with a history of transient ischemic attack(TIA), myocardial infarction(MI), unstable angina, cerebral infarction, cerebral hemorrhage, percutaneous transluminal angioplasty(PTA) or coronary artery bypass graft(CABG) within the last 6 months prior to the screening

11. Subject with severe heart failure(NYHA class III~IV), arrythmia requiring treatment

12. Subject with known hypersensitivity (anaphylaxis) to any component of the study drug

13. Subject who had received other immunoglobulin product within the last 3 months prior to the study entry

14. Subject who had received live parenteral vaccine (MMR, Cholera and Varicella) within the last 3 months prior to the study entry

15. Subject who had received estrogen or hormone alternative medicine

16. Pregnant or breast-feeding women

17. Woman of childbearing potential with positive pregnancy test confirmed by serum beta-human chorionic gonadotropin(B-HCG) test within 28 days prior to dosing by urine pregnancy or Subject who refused to use a reliable method of contraception

18. Alcohol or drug abuse within 6 months

19. Subject who has participated in any other clinical trial within 30 days

20. Subject who has any clinically meaningful disease investigator's judgement to prevent participating in this study

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
GC1102 80,000 IU
recombinant human hepatitis B immunoglobulin
GC1102 100,000 IU
recombinant human hepatitis B immunoglobulin
I.V HBIG
human anti-hepatitis B Immunoglobulin

Locations

Country Name City State
Korea, Republic of Seoul Asan Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Green Cross Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Other Pharmacokinetic(PK) parameters serum drug titer 1 year
Other Area under curve(AUC) area under the baseline corrected serum titer versus time curve from time 0 to time of the last measureable titer 1 year
Other clearance(CL) clearance 1 year
Other Vdss volume of distribution 1 year
Other Vdss/CL effective half-life 1 year
Other Adverse events Adverse events occured during clinical trials 1 year
Other Clinical abnormalities Clinical laboratory test 1 year
Primary Prevention Failure rate of HBV Seroconversion rate of HBsAg or HBeAg, anti-HBs < 500 IU/L 28weeks
Secondary Recurrence rate of HBV Seroconversion rate of HBsAg or HBeAg 28weeks
Secondary Prophylactic failure rate of HBV Seroconversion rate of HBsAg or HBeAg, anti-HBs < 500 IU/L 28weeks
Secondary Recurrence duration Seroconversion time of HBsAg or HBeAg 28weeks
Secondary Overall survival rate survival rate during 1 year 1 year
Secondary Geometric mean titer of HBV DNA Geometric mean titer(GMT) of HBV DNA 1 year
Secondary Change of anti-HBe anti-hepatitis B e(HBe) 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04704024 - Reducing Vertical Transmission of Hepatitis B in Africa Phase 3
Active, not recruiting NCT02143401 - Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT00371150 - Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection Phase 4
Completed NCT01788371 - Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus Phase 4
Recruiting NCT06368479 - Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Site Settings N/A
Completed NCT01488526 - Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus Phase 4
Terminated NCT02826018 - A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection Phase 1
Completed NCT01970254 - Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy
Completed NCT00489099 - A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054) Phase 3
Recruiting NCT03476083 - Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission Phase 4
Recruiting NCT03865966 - Hepatitis B Virus Infection After Liver Transplantation in Children
Completed NCT03627507 - Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh. Phase 2/Phase 3
Completed NCT02443233 - Evaluation of Paternal, Maternal and Obstetric Factors Leading to the Hepatitis B Immunization Failure in Hong Kong N/A
Completed NCT00841477 - An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users Phase 3
Terminated NCT03887702 - Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors Phase 3
Completed NCT02304315 - A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients Phase 2
Active, not recruiting NCT05117541 - Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection
Not yet recruiting NCT06368466 - A Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Sites N/A